BACKGROUND AND AIMS: It is a commonly held notion that patients with cirrhosis do not suffer from deep vein thrombosis (DVT) or pulmonary embolism (PE) because they are naturally anticoagulated. However, to date, no studies have been carried out that objectively address this issue. We conducted a study to examine the relationship between cirrhosis and DVT/PE events. METHODS: A case-control study of patients seen at a tertiary care hospital was performed. Cases were hospitalized patients with biopsy and/or imaging plus clinical evidence of cirrhosis. Well-matched patients with no known evidence of cirrhosis served as controls. The DVT/PE events were identified by the international classification of disease-9 (ICD-9) codes and confirmed with radiographic/nuclear imaging. The Charlson Index was calculated to determine the comorbidity. The incidence of DVT/PE in cirrhotic patients was also compared to patients with chronic kidney disease (CKD), congestive heart failure (CHF), and solid organ cancers. RESULTS: This study consisted of 963 cirrhotics and 12,405 controls. Both the incidence of DVT/PE (1.8 vs. 0.9%, P = 0.007) and Charlson Index scores (3.2 +/- 1.8 vs. 0.9 +/- 1.5, P < 0.001) were higher in cirrhotics than in the controls. However, in the multivariate analysis, the presence of cirrhosis was not associated with DVT/PE [odds ratio (OR) 0.87, P = 0.06]. Partial thromboplastin time (PTT; OR 0.88, P = 0.04) and serum albumin (OR 0.47, P = 0.03) were the independent predictors of DVT/PE. The incidence of DVT/PE in cirrhotics (1.8%) was lower than that in patients with other medical illnesses: 7.1% in CKD, 7.8% in CHF, and 6.1% in cancers. Conclusion Patients with cirrhosis do not have a lower risk of DVT/PE than non-cirrhotic controls without other significant co-morbidities, such as CHF, CKD, and solid organ cancers. Partial thromboplastin time and serum albumin were found to be independently predictive of DVT/PE in cirrhotic patients.
BACKGROUND AND AIMS: It is a commonly held notion that patients with cirrhosis do not suffer from deep vein thrombosis (DVT) or pulmonary embolism (PE) because they are naturally anticoagulated. However, to date, no studies have been carried out that objectively address this issue. We conducted a study to examine the relationship between cirrhosis and DVT/PE events. METHODS: A case-control study of patients seen at a tertiary care hospital was performed. Cases were hospitalized patients with biopsy and/or imaging plus clinical evidence of cirrhosis. Well-matched patients with no known evidence of cirrhosis served as controls. The DVT/PE events were identified by the international classification of disease-9 (ICD-9) codes and confirmed with radiographic/nuclear imaging. The Charlson Index was calculated to determine the comorbidity. The incidence of DVT/PE in cirrhotic patients was also compared to patients with chronic kidney disease (CKD), congestive heart failure (CHF), and solid organ cancers. RESULTS: This study consisted of 963 cirrhotics and 12,405 controls. Both the incidence of DVT/PE (1.8 vs. 0.9%, P = 0.007) and Charlson Index scores (3.2 +/- 1.8 vs. 0.9 +/- 1.5, P < 0.001) were higher in cirrhotics than in the controls. However, in the multivariate analysis, the presence of cirrhosis was not associated with DVT/PE [odds ratio (OR) 0.87, P = 0.06]. Partial thromboplastin time (PTT; OR 0.88, P = 0.04) and serum albumin (OR 0.47, P = 0.03) were the independent predictors of DVT/PE. The incidence of DVT/PE in cirrhotics (1.8%) was lower than that in patients with other medical illnesses: 7.1% in CKD, 7.8% in CHF, and 6.1% in cancers. Conclusion Patients with cirrhosis do not have a lower risk of DVT/PE than non-cirrhotic controls without other significant co-morbidities, such as CHF, CKD, and solid organ cancers. Partial thromboplastin time and serum albumin were found to be independently predictive of DVT/PE in cirrhotic patients.
Authors: Carmen M Stanca; Nancy Bach; Cynthia Krause; Nidhi Tandon; Maria A Freni; Julio A Gutierrez; Carol Bodian; Jose Lopez; Paul D Berk; Henry C Bodenheimer; Andrea D Branch; Joseph A Odin Journal: Am J Gastroenterol Date: 2005-05 Impact factor: 10.864
Authors: C J McDonald; J M Overhage; W M Tierney; P R Dexter; D K Martin; J G Suico; A Zafar; G Schadow; L Blevins; T Glazener; J Meeks-Johnson; L Lemmon; J Warvel; B Porterfield; J Warvel; P Cassidy; D Lindbergh; A Belsito; M Tucker; B Williams; C Wodniak Journal: Int J Med Inform Date: 1999-06 Impact factor: 4.046
Authors: Patrick G Northup; Matthew M McMahon; A Parker Ruhl; Scott E Altschuler; Agata Volk-Bednarz; Stephen H Caldwell; Carl L Berg Journal: Am J Gastroenterol Date: 2006-07 Impact factor: 10.864
Authors: John E Schrecengost; Robin D LeGallo; James C Boyd; Karel G M Moons; Steven L Gonias; C Edward Rose; David E Bruns Journal: Clin Chem Date: 2003-09 Impact factor: 8.327
Authors: Damian J Harding; M Thamara P R Perera; Frederick Chen; Simon Olliff; Dhiraj Tripathi Journal: World J Gastroenterol Date: 2015-06-14 Impact factor: 5.742
Authors: Pierre-Emmanuel Rautou; Kohei Tatsumi; Silvio Antoniak; A Phillip Owens; Erica Sparkenbaugh; Lori A Holle; Alisa S Wolberg; Anna K Kopec; Rafal Pawlinski; James P Luyendyk; Nigel Mackman Journal: J Hepatol Date: 2015-08-29 Impact factor: 25.083